Interpace Diagnostics Group Reports Second Quarter 2017 Financial Results, Business Progress and Recent ... - Nasdaq

Interpace Diagnostics Group Reports Second Quarter 2017 Financial Results, Business Progress and Recent ... Nasdaq The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation ... Interpace Diagnostics Group Inc. - Receive News & Ratings DailyThe Cerbat Gem all 4 news articles »

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vpXLLB
via IFTTT